Abstract: Provided are a method and device for updating an input method system, a computer storage medium, and a device. The method includes: receiving multiple operation logs from multiple user terminals on which the input method system is installed, the operation logs recording log entries which indicate an operations of input corresponding candidate items; extracting log entries from the received operation logs; determining a quantity of log entries of each type; and sending, according to the determined quantity, log entries in a preset type to the user terminals on which the input method system is installed, so as to update the input method system.

Abstract: Disclosed are a crystal form and a salt form of and a preparation method for a tyrosine kinase inhibitor.

Abstract: A compound represented by Formula I or pharmaceutically acceptable salt thereof. The present invention relates to a 4-arylamino quinazoline hydroxamic acid compound having a histone deacetylase inhibitory activity, preparation method of the compound, pharmaceutical composition comprising the compound, and use of the compound and the pharmaceutical composition in the preparation of a histone deacetylase inhibitor medicine. The present invention aims at acquiring, via a medicine design and a synthetic technology, a series of selective histone deacetylase inhibitors having good hypotype selectivity and favorable pharmacokinetic characteristics based on optimization of an enzyme surface recognition region and connection region of 4-arylamino quinazoline, thus reducing an effect on normal tissues or cells while improving an antineoplastic activity of the normal tissues or cells. In Formula I, the variables are as described herein.

Abstract: The present invention discloses a class of pyrrolidine derivatives as PPAR agonist, and their use for the treatment of some diseases of PPAR receptor-associated pathways (such as nonalcoholic steatohepatitis and concurrent fibrosis, insulin resistance, primary biliary cholangitis, dyslipidemia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, cardiovascular disease, obesity or the like). In particular, the present invention discloses a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: The invention discloses a crystal form A of a compound (I) and a preparation method thereof, and further discloses an application of the crystal form A as a PDE2 or TNF-? inhibitor.

Abstract: The present invention discloses a class of pyrrolidine derivatives as PPAR agonist, and their use for the treatment of some diseases of PPAR receptor-associated pathways (such as nonalcoholic steatohepatitis and concurrent fibrosis, insulin resistance, primary biliary cholgangitis, dyslipidenmia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, cardiovascular disease, obesity or the like). In particular, the present invention discloses a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNF? inhibitors, in particular, the compounds as shown in formula (I), or tautomers thereof or pharmaceutically acceptable salts thereof.

Abstract: The present invention relates to a tyrosine kinase inhibitor and a pharmaceutical composition comprising same.

Abstract: Virtualization software establishes multiple execution environments within a virtual machine, wherein software modules executing in one environment cannot access private memory of another environment. A separate set of shadow memory address mappings is maintained for each execution environment. For example, a separate shadow page table may be maintained for each execution environment. The virtualization software ensures that the shadow address mappings for one execution environment do not map to the physical memory pages that contain the private code or data of another execution environment. When execution switches from one execution environment to another, the virtualization software activates the shadow address mappings for the new execution environment. A similar approach, using separate mappings, may also be used to prevent software modules in one execution environment from accessing the private disk space or other secondary storage of another execution environment.

Abstract: A virtual-machine-based system that identifies an application or process in a virtual machine in order to locate resources associated with the identified application. Access to the located resources is then controlled based on a context of the identified application. Those applications without the necessary context will have a different view of the resource.

Abstract: A virtual-machine-based system that may protect the privacy and integrity of application data, even in the event of a total operating system compromise. An application is presented with a normal view of its resources, but the operating system is presented with an encrypted view. This allows the operating system to carry out the complex task of managing an application's resources, without allowing it to read or modify them. Different views of “physical” memory are presented, depending on a context performing the access. An additional dimension of protection beyond the hierarchical protection domains implemented by traditional operating systems and processors is provided.

Abstract: The invention discloses a crystal form A of a compound (I) and a preparation method thereof, and further discloses an application of the crystal form A as a PDE2 or TNF-? inhibitor.

Abstract: Hydroxyl purine compounds represented by formula (I), tautomers or pharmaceutically acceptable salts thereof, and applications thereof as PDE2 or TNF-? inhibitors.

Abstract: An antenna and a communications device are disclosed. The antenna includes: multiple feeders, a microstrip antenna array, and at least one energy attenuation circuit; the microstrip antenna array includes multiple array elements, where each of the multiple array elements is connected to a cable feeding port by using one of the multiple feeders; each of the at least one energy attenuation circuit is located at a feeder, where the feeder is one of the multiple feeders and is connected to an array element, and the array element is located at a periphery of the multiple array elements; and the energy attenuation circuit includes a resistor, where the resistor is grounded, and the resistor consumes a part of energy in the feeder when the resistor is grounded.

Abstract: A virtual-machine-based system that identifies an application or process in a virtual machine in order to locate resources associated with the identified application. Access to the located resources is then controlled based on a context of the identified application. Those applications without the necessary context will have a different view of the resource.

Abstract: Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNF? inhibitors, in particular, the compounds as shown in formula (I), or tautomers or pharmaceutically acceptable salts thereof.

Abstract: Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNF? inhibitors, in particular, the compounds as shown in formula (I), or tautomers thereof or pharmaceutically acceptable salts thereof.

Abstract: A compound represented by Formula I or pharmaceutically acceptable salt thereof. The present invention relates to a 4-arylamino quinazoline hydroxamic acid compound having a histone deacetylase inhibitory activity, preparation method of the compound, pharmaceutical composition comprising the compound, and use of the compound and the pharmaceutical composition in the preparation of a histone deacetylase inhibitor medicine. The present invention aims at acquiring, via a medicine design and a synthetic technology, a series of selective histone deacetylase inhibitors having good hypotype selectivity and favorable pharmacokinetic characteristics based on optimization of an enzyme surface recognition region and connection region of 4-arylamino quinazoline, thus reducing an effect on normal tissues or cells while improving an antineoplastic activity of the normal tissues or cells.

Abstract: Disclosed are quinoline derivatives as hedgehog pathway inhibitors, especially as SMO inhibitors. Compounds of the present invention can be used in treating diseases relating to hedgehog pathway including cancer.

Abstract: A virtual-machine-based system that may protect the privacy and integrity of application data, even in the event of a total operating system compromise. An application is presented with a normal view of its resources, but the operating system is presented with an encrypted view. This allows the operating system to carry out the complex task of managing an application's resources, without allowing it to read or modify them. Different views of “physical” memory are presented, depending on a context performing the access. An additional dimension of protection beyond the hierarchical protection domains implemented by traditional operating systems and processors is provided.